Our Team
Kokua has an experienced senior team with proven successful track records in biotechnology, clinical and inhaled product development
George H. Luciuk, MD, BSc, FRCPC
Over 35 years experience
Pediatrics, Allergist & Immunologist
Diplomate-American Board of Pediatrics
Diplomate-American Board of Allergy and Immunology
Past President, Allergy Section, Canadian Pediatric Society, June 1986 – 1988
Board of Directors, Canadian Society if Allergy and Clinical Immunology, 1987 – 1992
Medical Advisory Committee, B. C. Lung Association Research Centre
Patient/Public Education Committee, B. C. Lung Association
Consultant in Allergy /Immunology at North Hawaii Community Hospital, Kamuela, Hawaii
Simon Pimstone, MD, PhD, FRCPC
Over 25 years clinical, drug development and biotech experience including:
azetukalner (Ph3 epilepsy, MDD)
fluticasone propionate (Ph2 osteoarthritis, EOE)
Raised > $1B in capital markets, run and/or chaired public biotech companies (XENE, EPRX)
Kevin Stapleton, PhD
Over 26 years of inhalational drug product CMC and development experience, experience includes:
inhaled aztreonam (CF)
clofazimine (NTM)
dihydroergotamine (migraine)
levodopa (Parkinson’s) and insulin (diabetes)
Lisa Discepola, MSc
Over 27 years of clinical operations and development experience in pharma, biotech and CRO industries. Providing high-level development, regulatory and operational leadership from early development to regulatory approval. Prior to joining Kokua, Lisa supported multiple programs from Phase 1 to post marketing clinical trials in various therapeutic areas including the successful launch of immunosuppressant and anti-inflammatory agents for use in asthma, allergy and auto-immune indications.
